Immunosequencing for Cancer Immunotherapy Development
with Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies
Microfluidic 3D Cell Cultures and Organ Models for Drug Testing
with Jeffrey T. Borenstein, Ph.D., Laboratory Technical Staff, Biomedical Microsystems, Draper Laboratory
A Conversation on Modern Lead Generation Strategies
with Joerg Holenz, Ph.D., Director, Discovery and Preclinical Sciences; Project Leader, Neuroscience iMed, AstraZeneca Neuroscience
Challenges and Future Directions of Blood-Brain Barrier Research
with Robert D. Bell, Ph. D., Principal Scientist, Integrative Neuroscience, Pfizer
Animal Models and Combination Therapy
with Cory Abate-Shen, Ph.D., Michael and Stella Chernow Professor of Urological Oncology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center
Pain and the Brain: Using Patient-Derived Neurons for Preclinical Phenotypic Screening
with Elizabeth D. Buttermore, Ph.D., Research Fellow, F.M. Kirby Neurobiology Center, Boston Children's Hospital; Neurobiology Department, Harvard Medical School
Tissue Stem Cells, Tumors, Toxicity and Time
with James L. Sherley, M.D., Ph.D., Director, Asymmetrex, LLC
Chemical Route Development of HCV Protease-Inhibitor, Telaprevir
with Dr. Gerald Tanoury
How HIGH Can You Get? Using in vitro Data to Reduce Animal Experiments & Enabling Forms in Discovery-Development Interface
with Dr. Geeti Gangal
Development of Poorly Soluble Drug: Current and Future Perspectives on Dissolution Prediction and Experimentation
with Robert A. Bellantone, Ph.D.
Exploring and Optimizing Cost-Effective Route toward DPP-IV Inhibitor Compounds
with Nhut Diep, Ph.D.
Dr. Renato Skerlj, founder of Drug Discovery Consulting LLC and former Head of Small Molecule Discovery at Genzyme, and CHI's Dr. Edel O'Regan, discuss hot topics in medicinal chemistry including: residence time, covalent inhibition, beyond the rule-of-five, protein-protein interactions, macrocycles.
Dr. Stewart Fisher, Principal at SL Fisher Consulting and former Executive Director at AstraZeneca, discusses allosteric inhibition, natural product chemistries, covalent inhibition strategies and binding kinetics in drug discovery.
In part two of his conference preview, Dr. Fisher discusses the importance of receptor binding kinetics and the role of residence time.
Technological Advances in Preclinical Imaging: What to Expect with Erik M. Shapiro, Ph.D.
Alzheimer’s Targets and the Path to the Clinic with Dennis Selkoe and Corinne Augelli-Szafran
Preclinical and Clinical Update with Keynote Speaker, Kuldip Dave from the MJFF